2872
Views & Citations1872
Likes & Shares
Basic helix-loop-helix (bHLH) transcription factors
DEC1 (BHLHE40) and DEC2 (BHLHE41) have been reported to associate with the
regulation of apoptosis, cell proliferation, circadian rhythms and malignancy
in various cancers. Our previous study suggested that DEC2 inhibited
paclitaxel-induced apoptosis in castration-resistant prostate cancer (CRPC)
DU145 and PC-3 cells. In the present study, we investigated the roles of DEC1
and DEC2 in human castration-sensitive prostate cancer LNCap cells in response
to paclitaxel. Paclitaxel increased the expression of DEC1/DEC2 in LNCap cells.
We found that DEC1 siRNA decreased the amount of cleaved poly (ADP-ribose)
polymerase (PARP) and cleaved caspase-8, whereas increased that of Bcl-xL. In
addition, DEC1 overexpression increased the protein level of cleaved PARP and
cleaved caspase-8, whereas decreased Bcl-xL expression. On the contrary, DEC2
siRNA upregulated the amount of cleaved PARP and cleaved caspase-8 but downregulated
Bcl-xL regardless of paclitaxel. Corresponding results were obtained in
DEC2-overexpressed LNCap cells. These data indicated that DEC1 and DEC2 have
pro-apoptotic and anti-apoptotic effects in paclitaxel-induced apoptosis of
LNCap cells, respectively.
Keywords: DEC1,
DEC2, Paclitaxel, Apoptosis, Prostate cancer, LNCap cells
INTRODUCTION
Prostatic
cancer remains the most common cancer and the second most leading cause of
cancer deaths in industrial countries [1]. Androgen deprivation therapy (ADT)
beneficially effects on the control of androgen-dependent tumors, however,
after a short-term remission, surviving cancer cells often re-growth with
increased malignancy [2]. Taxane-based chemotherapy is a
recommended therapeutic approach to treat patients recurring from ADT.
Paclitaxel, a natural diterpenoid isolated from the stem bark of Taxus, has
become a research focus for decades because of its complex structure, unique
therapeutic mechanism and excellent anticancer activities [3]. By promoting
tubulin assembly and stabilizing microtubules, paclitaxel can inhibit mitosis
and finally leads to apoptosis of tumor cells [4]. Paclitaxel has significant
effect in a variety of cancers, including several refractory tumors such as
ovarian carcinoma, acute myeloid leukemia, castration-resistant prostate cancer
(CRPC) [5-7]. Molecular mechanisms of paclitaxel in anti-cancer therapy involve
the activation of c-Jun N-terminal kinase (JNK), downregulation of
Bcl-2/Bcl-xL, activation of caspases and poly (ADP-ribose) polymerase (PARP)
[8-11], and leading to cell growth arrest at the G2/M phase of the cell cycle
[12].
Differentiated embryonic chondrocyte gene
(DEC) 1 and DEC2 belong to basic helix-loop-helix (bHLH) transcription factor
family, and function as regulators of cell proliferation, circadian rhythm,
cancer progression, as well as targets of hypoxia [13-16]. We previously reported that DEC1
and DEC2 differentially regulated apoptosis, i.e., DEC1 promoted, while
DEC2 inhibited apoptosis of human breast cancer MCF-7 cells [17]. We also found
that DEC2 negatively regulated paclitaxel-induced apoptosis in CRPC cells DU145
and PC-3 [18]. However, the roles of DEC1/DEC2 in apoptosis of
CSPC cells are not well known.
The objective of the current study was to investigate the roles of
DEC1/DEC2 in paclitaxel-induced apoptosis of LNCap cells. Our results
demonstrated that DEC1 and DEC2 have pro-apoptotic and anti-apoptotic effects
in paclitaxel-treated LNCap cells, respectively.
MATERIALS AND METHODS
Cell culture: Human
prostate cancer LNCap. FGC cells (RIKEN BRC through the National Bio-Resource
Project of the MEXT, Japan) were cultured in RPMI-1640 medium supplemented with
10% fetal bovine serum at 37°C in a humidified atmosphere (95% air, 5% CO2).
Cells were treated with different concentrations of paclitaxel (Sigma-Aldrich,
St. Louis, MO, USA) for the indicated period of time.
RNA interference for knockdown of DEC1/DEC2: Short interference
RNA (siRNA) for
silencing DEC1 or DEC2 was synthesized by Invitrogen (Thermo Fisher Scientific
Inc., Waltham, MA, USA). The sequences of DEC1, DEC2, and the negative control
siRNA have been described previously [19]. 5×104 cells were seeded
per 35-mm well and transfected with siRNA against DEC1 or DEC2, or negative
control siRNA using Lipofectamine RNA iMAX reagent (Invitrogen) according to
the manufacturer’s protocol. The cells were treated with paclitaxel for 24 h
and collected for western blot analysis.
Overexpression of DEC1/DEC2: Human DEC1 or DEC2 expression
plasmids (DEC1 pcDNA, DEC2 pcDNA) were kindly gifted from Dr. Katsumi Fujimoto
(Hiroshima University, Japan) [14]. 5×104 cells were seeded per
35-mm well and cultured for at least 24 h. DEC1 or DEC2 expression plasmid was
introduced into the cells with Lipofectamine LTX reagent (Invitrogen) for 18 h.
The transfected cells were subsequently incubated with paclitaxel for 24 h and
collected for western blot analysis.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR): Triplicate RNA samples from LNCap cells were
prepared for RT-qPCR. RNA was extracted using an RNeasy Mini kit (Qiagen,
Hilden, Germany) and was used for reverse transcription according to the
manufacturer’s instructions. First cDNA was synthesized from 1 μg of total RNA
using ReverTra Ace (Toyobo Co., Ltd., Osaka, Japan). Quantitative PCR was
performed using Taq PCR Master Mix
Kit (Qiagen). The primer sequences and product sizes of DEC1, DEC2 and GAPDH
were described previously [19]. The cDNAs for DEC1, DEC2 and GAPDH were amplified
at 27 cycles, 27 cycles and 20 cycles, respectively. The PCR products were
analyzed by electrophoresis on 1.5% (w/v) agarose gels stained with ethidium
bromide.
Western blotting: The cells were lysed using M-PER lysis buffer (Thermo Scientific, Waltham,
MA, USA), and the bicinchoninic acid (BCA) assay was used for determining the
protein concentrations. The lysates (10 μg protein) were subjected to
SDS-PAGE, and the separated proteins were transferred to PVDF membranes
(Immobilon P, Merck Millipore, Billerica, MA, USA). Western blot bands were
detected by Bio-Rad systems (Bio-Rad, Hercules, CA, USA) with the ECL-prime or
ECL-select detection systems (GE Healthcare, Wauwatosa, WI, USA).
Cell viability assay: Cells seeded in 96-well plate were cultured
with indicated doses of paclitaxel for 24 h. In the case of combination
treatment, cells were transfected with pcDNA or DEC2 pcDNA for 18 h on ahead,
and then cultured in the medium containing 50 μM of paclitaxel for 24 h. The
pcDNA-transfected cells without paclitaxel treatment were used as control. The
cell viability was detected with MTS [3-(4,
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]
assay as described previously [20].
Statistical analysis: Each
experiment was repeated in triplicate and data are presented as means ±
standard deviation. The ordinary one-way ANOVA analysis was performed using
GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered as statistical
significance.
RESULTS
DEC1/DEC2 expression in LNCap cells treated with paclitaxel
Firstly, we analyzed the expression of apoptosis markers and DEC1/DEC2 of
LNCap cells in response to paclitaxel. Paclitaxel induced the cleavage of PARP
and caspase-8 at the concentration of 10 μM, and reached maximum at 100 μM.
When referred to anti-apoptotic factor Bcl-xL, lower doses of paclitaxel failed
to decrease Bcl-xL expression, whereas higher doses of paclitaxel (such as 50
μM and 100 μM) inhibited its expression. Additionally, no significant changes
of caspase-9 and Bax were observed (Figure
1A). The protein and mRNA levels of DEC1/DEC2 were upregulated in a concentration-dependent
manner when treated with paclitaxel for 24 h (Figure 1, B and C).
DEC1 promoted apoptosis of LNCap cells
treated with paclitaxel
In paclitaxel-untreated LNCap cells, knockdown or overexpression of
DEC1 failed to induce the cleavage of PARP and caspase-8 (Figure 2, A and B). However,
in the presence of 50 μM of paclitaxel, DEC1 functioned as a positive regulator
of apoptosis, that is, the amounts of cleaved PARP and cleaved caspase-8 were
decreased by DEC1 siRNA but were increased by DEC1 pcDNA. On the other hand,
DEC1 negatively correlated with the anti-apoptotic protein Bcl-xL regardless of
paclitaxel treatment (Figure 2, A and B).
DEC2 inhibited apoptosis no matter with paclitaxel in LNCap cells
To
analyze the roles of DEC2 in apoptosis of LNCap cells, the siRNA or plasmid of
DEC2 was transfected into LNCap cells and similar analyses with those mentioned
above were carried out. The amounts of cleaved PARP and cleaved caspase-8 were
slightly increased when knockdown of DEC2 only, but were significantly
increased when combined with paclitaxel (Figure
3A). Besides, the expression of Bcl-xL, which was decreased by DEC2
knockdown, was further inhibited under paclitaxel treatment. In corresponding
with these results, we got opposite
expression styles of apoptosis-related factors in DEC2 pcDNA-transfected LNCap cells (Figure 3B).
DEC2 protected LNCap cells from paclitaxel-induced apoptosis
By using MTS assay, we found that paclitaxel decreased the number of
viable cells (Figure 4A). Next, we
examined whether DEC2 overexpression affected the cell viability in LNCap
cells. DEC2 overexpression in the presence of paclitaxel (50 μM) markedly
upregulated the cell viability compared with the paclitaxel-treated control.
Moreover, DEC2 overexpression without paclitaxel treatment exhibited little
effect on the cell viability (Figure 4B).
DISCUSSION
We
previously demonstrated the roles of DEC1/DEC2 in paclitaxel-induced apoptosis
of human castration-resistant prostate cancer (CRPC) cell lines DU145 and PC-3.
Our results exhibited that DEC1 had pro-apoptotic effects, while DEC2 had
anti-apoptotic effects on paclitaxel-induced apoptosis in the two cell lines
[18]. The present study focused on the DEC functions in human
castration-sensitive prostate cancer (CSPC) LNCap cells. The CSPC cells were
chosen since a majority of early-stage prostate cancer patients showed androgen
dependent growth. Paclitaxel upregulated cleaved PARP at the concentration of
10 μM in LNCap cells, which was lower than those of DU145 or PC-3 cells [18].
Meanwhile, paclitaxel induced DEC1/DEC2 expression in a concentration-dependent
manner. To further examine the roles of DEC genes in apoptosis, the siRNAs or
the expression plasmids of DEC1 or DEC2 were transiently transfected into the
LNCap cells. When LNCap cells were exposed to paclitaxel, DEC1 overexpression
augmented paclitaxel-induced apoptosis. In addition, DEC1 negatively related to
the anti-apoptotic molecular Bcl-xL independent of paclitaxel. However, the
cleavage of caspase-8 and PARP occurred only in the presence of paclitaxel.
DEC1 was proposed to cause apoptosis by combining with other proteins and
function as a helper or an enhancer in paclitaxel-induced apoptosis pathway. On
the other hand, knockdown of DEC2 by siRNA remarkably caused the cleavage of
caspase-8, and paclitaxel furthered this effect.
Unlike DEC1, DEC2 positively correlated with Bcl-xL expression in LNCap
cells. These data indicated an anti-apoptotic effect of DEC2 in paclitaxel
treatment. Although DEC2 suppressed apoptosis induced by paclitaxel, we finally
obtained the cleaved caspase-8 and cleaved PARP in paclitaxel-treated LNCap cells.
Consideration of these results, we deduced that DEC1 was more effective in
paclitaxel-induced apoptosis process than DEC2. The differences in the
functions of DEC1 and DEC2 have been concluded in our previous reports [18]. We
concluded that DEC2 functioned as an ‘anti-apoptotic factor’ mainly through
regulating Bcl2 family proteins, including the anti-apoptotic subfamily member
Bcl-2 [17] and Bcl-xL, as well as the pro-apoptotic member such as Bim [21].
Members of Bcl-2 family play a central role in monitoring cell growth
and proliferation and in modulating the genetic programs of the organisms [22].
We examined the expression of several members as those mentioned in previous
report [18]. However, Bcl-2 protein could not be detected in LNCap cells (data
not shown), and the expression of Bax and Bad (data not shown) kept constant
among various kinds of treatment. The mechanism by which DEC2 regulating the
Bcl2 family members was needed to be clarified. The distinction of its targets
upon different treatment methods should be taken into consideration in our
future studies.
We confirmed that DEC2 functioned as an anti-apoptotic factor in human
castration-sensitive prostate cancer cell line LNCap. The data of the current
study further evidenced our hypothesis that DEC2 would be an ‘inhibitor’ of
apoptosis. Suppressing DEC2 expression may become one of the choices in
clinically therapy of prostate cancer as well as other cancers.
ACKNOWLEDGEMENTS
This study was supported by JSPS KAKENHI, Grants-in-Aid from the Ministry
of Education, Culture, Sports, Science and Technology of Japan (Grant No.
17K17575, and No. 17H04057).
1. Siegel
RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65: 5-29.
5. McGuire
WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, et al. (1989) Taxol:
a unique antineoplastic agent with significant activity in advanced ovarian epithelial
neoplasms. Ann Intern Med 111: 273-279.
6. Rowinsky EK, Burke PJ, Karp JE, Tucker RW,
Ettinger DS, et al. (1989) Phase I and pharmacodynamic
study of taxol in refractory acute leukemias.
Cancer Res 49: 4640-4647.
14. Honma S, Kawamoto T, Takagi Y, Fujimoto K, Sato F, et al. (2002)
Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature 419: 841-844.
15. Li Y, Xie M, Yang J, Yang D, Deng R, et al. (2006)
The expression of antiapoptotic protein survivin is transcriptionally
upregulated by DEC1 primarily through multiple sp1 binding sites in the
proximal promoter. Oncogene 25:
3296-3306.
20. Wu Y, Sato H, Suzuki T, Yoshizawa T, Morohashi S, et al. (2015)
Involvement of c-Myc in the proliferation of MCF-7 human breast cancer cells
induced by bHLH transcription factor DEC2.
Int J Mol Med 35: 815-820.
21. Wu Y, Sato F, Bhawal UK, Kawamoto T, Fujimoto
K, et al. (2012) BHLH transcription factor DEC2
regulates pro-apoptotic factor Bim in human oral cancer HSC-3 cells. Biomed Res 33: 75-82.
22. Cory
S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death
switch. Nat Rev Cancer 2: 647-656.
QUICK LINKS
- SUBMIT MANUSCRIPT
- RECOMMEND THE JOURNAL
-
SUBSCRIBE FOR ALERTS
RELATED JOURNALS
- Journal of Nursing and Occupational Health (ISSN: 2640-0845)
- Journal of Pathology and Toxicology Research
- Journal of Cancer Science and Treatment (ISSN:2641-7472)
- Advance Research on Endocrinology and Metabolism (ISSN: 2689-8209)
- Archive of Obstetrics Gynecology and Reproductive Medicine (ISSN:2640-2297)
- Journal of Oral Health and Dentistry (ISSN: 2638-499X)
- Journal of Carcinogenesis and Mutagenesis Research (ISSN: 2643-0541)